CTIS2022-502997-18-00招募中1 期
IM034-1014
Bristol-Myers Squibb Services Unlimited Company0 个研究点目标入组 64 人开始时间: 2023年5月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study in women with overweight or obesity to test whether different doses of BI 456906 influence the amount of a contraceptive in the bloodpharmacokinetic trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2022-503146-53-00Boehringer Ingelheim International GmbH24
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
A study in healthy men to test whether itraconazole influences the amount of BI 1584862 in the bloodHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-503542-31-00Boehringer Ingelheim International GmbH14
进行中（未招募）
1 期
A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesityCTIS2024-512332-29-00Boehringer Ingelheim International GmbH30
招募中
1 期
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimabhead and neck squamous cell carcinoma, non-small cell lung cancer or, melanomaCTIS2024-514034-20-00Boehringer Ingelheim International GmbH13